Kalaris Therapeutics, Inc. (KLRS)

Market Cap	56.18M -61.1%
Revenue (ttm)	n/a
Net Income	-44.26M
EPS	-2.06
Shares Out	23.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	104,424
Open	2.460
Previous Close	2.500
Day's Range	2.360 - 2.550
52-Week Range	2.350 - 11.880
Beta	n/a
Analysts	Buy
Price Target	18.71 (+692.8%)
Est. Earnings	Nov 11, 2026

About KLRS

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeut...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 20
• Stock Exchange: Nasdaq
• Ticker Symbol: KLRS
• Website: https://kalaristx.com

Analyst Summary

According to 8 analysts, the average rating for KLRS stock is "Buy." The 12-month stock price target is $18.71, which is an increase of 692.80% from the latest price.

Price Target

$18.71

(692.80% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error